Posted by Michael Wonder on 05 Aug 2021
ICER publishes final evidence report and policy recommendations on aducanumab for Alzheimer’s disease
5 August 2021 - Independent appraisal committee unanimously determined the evidence is not adequate to demonstrate that aducanumab provides a net health benefit.
The ICER today released a Final Evidence Report assessing the comparative clinical effectiveness and value of aducanumab (Aduhelm, Biogen) for the treatment of Alzheimer’s disease.
ICER’s report was reviewed at the July 2021 public meeting of the California Technology Assessment Forum, one of ICER’s three independent evidence appraisal committees.
